# Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

> **NCT03503799** · — · ACTIVE_NOT_RECRUITING · sponsor: **North Eastern German Society of Gynaecological Oncology** · enrollment: 1191 (actual)

## Conditions studied

- Primary Invasive Breast Cancer
- Estrogen Receptor Positive Tumor
- Human Epidermal Growth Factor Receptor 2 Negative Tumor

## Interventions

- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT03503799
- **Lead sponsor:** North Eastern German Society of Gynaecological Oncology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-17
- **Primary completion:** 2032-10-01
- **Final completion:** 2032-10-01
- **Target enrollment:** 1191 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503799, "Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03503799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*